Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lovenox Patent Invalidity Ruling Could Open Door To Near-Term Generics

This article was originally published in The Pink Sheet Daily

Executive Summary

California court invalidates Sanofi-Aventis’ patent due to inequitable conduct. The court’s ruling will lead to lifting of 30-month stay on ANDA approvals. Amphastar and Teva said they would await FDA approval of their enoxaparin generics before deciding whether to launch prior to an appellate court ruling.

You may also be interested in...



Court Rules Against Sanofi In Lovenox Patent Case Again; Second Round Of Appeals Likely

Denial of a second appeal of a U.S. District Court’s decision that Teva and Amphastar are not infringing the Lovenox patent could open door to generic launches.

Court Rules Against Sanofi In Lovenox Patent Case Again; Second Round Of Appeals Likely

Denial of a second appeal of a U.S. District Court’s decision that Teva and Amphastar are not infringing the Lovenox patent could open door to generic launches.

Lovenox’ Days In Court

Sanofi-Aventis begins a patent challenge case with Sandoz while a similar suit against Amphastar and Teva moves forward.

Related Content

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel